SCHEMBL6285430

SCHEMBL6285430

CC(=NNC(=N)N)c1cn(S(=O)(=O)c2ccccc2)c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFSF11 O14788 7/20 0.45
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
PLK1 P53350 1/20 0.41
HTR6 P50406 1/20 0.40
MAPT P10636 3/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
TNF P01375 2/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C1 Q04828 1/20 0.37
F2 P00734 1/20 0.37
PRSS1 P07477 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285427 1.00 TNFSF11 (0.45) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6278577 0.90 LMNA (0.47) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6278578 0.90 LMNA (0.47) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6286978 0.85 HTR6 (0.47) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6285062 0.85 LMNA (0.46) LMNASMN1; SMN2KMT2AMEN1PLK1
SCHEMBL6285182 0.85 LMNA (0.46) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6285056 0.85 LMNA (0.46) LMNASMN1; SMN2KMT2AMEN1PLK1
SCHEMBL6286980 0.85 HTR6 (0.47) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6285187 0.85 LMNA (0.46) TNFSF11LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6286906 0.84 LMNA (0.60) TNFSF11LMNASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A TNFSF11 1597/4885LMNA 4212/4885SMN1; SMN2 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.